Background: Around 25% of oral cavity squamous cell carcinoma (OCSCC) are not controlled by standard of care. Identifying those patients could offer them possibilities for intensified and personalized regimen. However, there is currently no validated biomarker for OCSCC patient selection in a pretreatment setting.
INTRODUCTION
Oral cavity squamous cell carcinoma (OCSSC) patients treated by primary surgery undergo post-operative surveillance, adjuvant radiotherapy, or chemo-radiotherapy, according to clinical and histopathological parameters that include disease stage, nodal involvement, extranodal extension (ENE), perineural invasion (PNI), vascular embols (VE) and resection margin status (1). Despite those numerous clinical decision parameters, around 25% of OCSCC will present an unpredictable early and/or severe recurrence (2), (3), (4) . Even the local failures that are eligible to the best treatment option, that is salvage surgery (5) , (6), (7) , have a poor prognosis with a median overall survival ranging from 20 to 30 months (4), (8) . Accurately identifying those high-risk patients would allow proposing them an intensified and risk-adjusted therapy, such as neoadjuvant chemotherapy or immunotherapy.
Neoadjuvant chemotherapy has failed to show benefit in head and neck squamous cell carcinoma (HNSCC), possibly because trials were made in unselected Stage III/IV HNSCC population (9) , (10) .
Immunotherapy is a new treatment modality, and its interest as neoadjuvant treatment is currently being evaluated (11) , (12) , (13) . Numerous prognostic markers have been proposed for OCSCC, but none of them has shown independent validation, and translation to clinical practice (14) . In this study, we used a biology-driven exploratory strategy, in order to identify a robust predictive biomarker for early severe recurrence and disease related death in primary OCSCC after treatment by standard of care. We found MMP2 as fulfilling those criteria, and when combined to nodal involvement, providing a simple and efficient patient stratification scheme.
RESULTS

Human primary tumor secretome analysis identified 29 deregulated molecules
To identify candidate biomarkers, we chose an unbiased approach applied to human primary tumors, in order to ensure physiopathological relevance. We used a tumor explant-culture system to analyze the soluble microenvironment in a prospective discovery cohort of 37 OCSCC patients treated by primary surgery (Table S1 ). Fresh standardized tumor and juxtatumor (non-involved) specimens were cultured for 24h at 37°C, and we measured a panel of 49 soluble molecules relevant to multiple cancer pathways, such as immunity, chemotaxis, tumor growth, angiogenesis, and tissue remodeling. We identified 25 molecules increased, and 4 decreased, in the tumor tissue ( Fig 1, Table S2 ). CXCL9, the metalloproteinases (MMP) MMP1, MMP2 and MMP9, plasminogen activator inhibitor (PAI-1) and resistin were among the molecules most increased in tumors, and MCP-1 (CCL2) in juxtatumors. SCF, multiple cytokines (IL-1b, TNFa, IL-15), growth factors (GM-CSF, VEGF) and chemokines (MDC, TARC) were also increased in the tumor, as compared to juxta-tumor samples (Fig 1) . The cytokines IL-9, TNFb, TSLP, IL-21 were never detected (Fig 1) . This provided a global, unbiased protein level profiling of the OCSCC tumor secretome.
High levels of soluble MMP2 were associated with poor prognosis
Patients were classified as severe if they had a disease-specific survival (DSS) of less than 36 months and /or a disease-free survival (DFS) of less than 12 months, and could not achieve a second remission (unsuccessful salvage procedures and/or permanent palliative treatment). Among the 29 deregulated secretome molecules, analyzed as candidate biomarkers, MMP2 was the only molecule expressed at significant higher levels among severe patients as compared to non-severe (p = 0.007) (Table S3 ). ROC curve defined 29.3 ng/ml as the optimal cut-off for soluble MMP2, with a sensitivity of 100% and a specificity of 71.4 % to identify severe cases (Fig2A). MMP2high tumors were associated with reduced DSS (p = 0.001), overall survival (OS) (p = 0.012) and DFS (p = 0.003) ( Fig 2B) .
Soluble MMP2 levels were independent of T cell infiltration
MMP degrade the extra-cellular matrix and promote tumor cell invasion (15) . Tissue damage may lead to a local increase in danger signals, and initiate an innate and then adaptive immune response. Thus, we hypothesized that MMP2 levels might influence T cell infiltration. Paired CD3 and CD8 T cell quantification by flow cytometry, and soluble MMP2 quantification, was available for 18 HNSCC patients. MMP2 was not significantly correlated to CD3 (r = 0.01, Spearman correlation coefficient) ( Fig   2C) nor to CD8 infiltration (r = -0.13, data not shown). Conversely, CD3 and CD8 infiltration were highly correlated to CXCL9 (r = 0.78 and r = 0.79) and CXCL10 (both r = 0.66) ( Fig 2C, data not shown for CD8). In the secretome analysis of the 37 OCSCC samples, MMP2 was not correlated to CXCL9 and CXCL10 (r=0.19 and r=0.09), further supporting that MMP2 levels were not associated to T cell infiltration ( Fig 2D) .
RNA levels of MMP2, CD276, CXCL10, and STAT1 predicted prognosis
To independently validate the prognostic value of MMP2, we measured a 30 genes panel (Table S4) 
by
RTqPCR in a large retrospective cohort of 145 OCSCC patients treated by primary surgery. Gene panel included MMP-2, -1, -9, other immune-related genes, and a published 18-gene signature predictive of the response to anti-PD-1 immunotherapy (16) . Patients' characteristics are available in Table 1 . Significant variables in univariate analysis for DSS, OS and DFS are listed in Table 2 . Among the clinical variables, tumor differentiation index, stage, ENE, VE and PNI were significant for both DSS and OS, while only the latter three were significant for DFS. Among the genes, high levels of MMP2 were associated to reduced DSS, OS and DFS. High levels of CD276 (B7-H3) and low levels of CXCL10 and STAT1 were also among the 5 and 11 genes associated to reduced DSS and OS, respectively ( Table 2 ). This validated the prognostic impact of MMP2, measured by two different methods (protein and mRNA), in a large OCSCC cohort.
MMP2 RNA, ENE, PNI and stage were independent prognostic factors
To identify clinical and biological parameters significant in multivariate analysis, we performed two Cox proportional hazards models. Model 1 included all the 145 patients and all clinical and biological variables significant in univariate analysis, except PNI and VE, because of missing values in 21 patients (14%),
whereas Model 2 included all significant variables, but was restricted to the 124 patients with complete data ( Fig 3A, Table S5 ). In both models MMP2high was an independent prognostic factor for DSS and DFS (Model 1 DSS: p = 0.001, DFS: p = 0.006, Model 2 DSS: p = 0.034, DFS: p = 0.016). For DSS, ENE status (p = 0.006) and PNI (p = 0.020) were also significant in Model 1 and 2, respectively. For DFS, ENE status was also significant in Model 1 (p = 0.006), but MMP2 was the only significant parameter in Model 2. For OS, MMP2 (p = 0.015) and stage (p = 0.042) were significant in Model 1, and PNI (p = 0.01) and stage (p = 0.019) were significant in Model 2 ( Fig 3A, Table S5 ). We defined prognostic groups using the parameters identified in multivariate analysis by the Model 1 to analyze the largest cohort of 145 patients. Table S6 ). MMP2 status induced clinically relevant variations in survival.
MMP2high vs MMP2low tumor bearing patients had a 5-year DSS of 61% versus 88% when ENE was absent, and of 36% versus 52% when ENE was present ( Table 3) . MMP2high tumors were associated to the presence of metastatic lymph node (p = 0.031), low or intermediate mitotic index (p = 0.001) and the presence of PNI (p = 0.02) (Table S7 ).
MMP2 may be used as a biomarker to select patients for treatment intensification
MMP2 RNA status was an efficient prognostic biomarker as measured by ROC curves according to severity criteria, in the whole 145 patient cohort (AUC = 0.66, p = 0.003), and among the ENE negative patients (n = 106, AUC = 0.71, p = 0.003) ( Fig S1) . The optimal thresholds were 1.81 and 1.82, which led to high negative predictive values (NPV) of 82% and 88% respectively, but lower positive predictive values (PPV) of 41% and 36%. For 29 patients, both soluble MMP2 and MMP2 RNA data were available, which allowed us to observe that both biomarkers were significantly correlated (Spearman r = 0.45, p = 0.016) ( Fig S2) , suggesting that MMP2 protein or RNA levels can be used as biomarker.
The expression of an 18-gene signature predictive of response to PD-1 blockade was similar between the different prognostic groups
The proportions of patients expected to respond to immunotherapy may vary between the prognostic groups defined above, and have consequences on the type of treatment that could be proposed in a riskadjusted strategy. Therefore, we measured the expression of an 18-gene signature (18G) (16) that is a predictive biomarker of response to PD-1 blockade. The 18G signature is composed of a core of 17 highly correlated genes (all Spearman correlation coefficients of the 17genes > 0.455), and CD276 ( Fig S3, Fig   S4) . 18G score was moderately increased in MMP2high tumors (p = 0.019) ( Fig S4, Fig S5) , but was similar whatever the ENE status (p=0,671) and disease stage (p = 0.513) ( Fig S5) . The 18G score was similar between the prognostic groups defined by MMP2 RNA and ENE status (p=0.119), MMP2 RNA status and Stage (p = 0.051), MMP2 RNA and PNI statuses (p = 0.089), and stage and PNI status (p = 0.661) ( Fig 3C) . This suggests that various prognostic groups may show response to anti-PD-1 therapy, with implications for the design of biomarker-driven trials in untreated resectable OCSCC patient with the goal of limiting early and severe recurrences ( Fig S6) .
DISCUSSION
In this study, we identified MMP2 as an independent prognostic biomarker for severe outcomes in OCSCC patients treated by primary surgery.
First, we prospectively produced and analyzed tumor and juxtatumor secretomes, which revealed 29 deregulated soluble molecules, the majority of them being upregulated in the tumor tissue. Those molecules belonged to various biological classes such as MMPs, chemokines, interleukins, adipokines and growth factors. One may consider that all these deregulated proteins reflect mechanisms of tumor progression, and could be candidate biomarkers. However, only soluble MMP2 was associated to poor prognosis in our study. Primary tumor-derived supernatant is not a widely applied method for biomarker identification and data on OCSCC secretome are scarce (17) if we exclude cancer cell-line derived supernatants. A database for healthy body fluids proteome was created in 2008, highlighting the general interest for such approach (18) . Here, we cannot exclude that tissue handling, although limited to the minimum in our protocol, may have induced or enhanced the production of some proteins, but this limitation was partially overcome by the comparison with paired juxtatumor supernatant. By the mean of an ultrafiltration catheter, interstitial fluid from a single HNSCC patient was analyzed and revealed 525 proteins by mass spectrometry, but the method was not applicable to juxtatumor tissue, which limited the potential to identify candidate biomarkers (19) . Another difficulty is that tumor secretome needs to be produced prospectively using fresh tumor samples, which limits the access to large cohorts with sufficient follow-up in order to identify prognostic biomarkers. However, we could overcome these difficulties, and our study illustrates the added value of this approach in providing data with strong biological relevance.
For further validation, we designed a homogenous retrospective cohort of patients with the same clinical setting of resectable OCSCC treated by primary surgery, and extracted tumor RNA from biobanked frozen samples to ensure the best quality of RNA (20) . Univariate analysis confirmed the prognostic value of MMP2 to predict DSS, OS and DFS. High levels of CD276 and low levels of CXCL10 and STAT1 were also associated to reduced DSS and OS, but only MMP2 remained significant in multivariate analysis.
Several studies have proposed MMP2 as a prognostic biomarker for OCSCC, but all had important limitations, such as the absence of multivariate analysis (21) , (22) , (23) , the inclusion of heterogeneous head and neck cancer patients with different tumor locations and treatments (24) , (25) , or retrospective cohorts with less than 60 patients (22) , (23), (26) , (27) . Most of these studies quantified MMP2 by immunohistochemistry (IHC) through semi-quantitative methods. Our study provided unbiased and definite evidence for the independent prognostic role of MMP2, in a large homogeneous OCSCC cohort, within a multivariate prognostic model.
The biological basis explaining why MMP2 is associated with poor prognosis is well known. MMP2 degrades type IV collagen and promotes epithelial-mesenchymal transition and metastasis (15), (28).
MMP may also skew the anti-tumor immune response by their effect on immune cells (29). MMP2 is secreted in an inactive form (pro-MMP2) and is activated by MMP1 (30) and MMP14 (31). Many cell types may produce MMP2, but fibroblasts seem to be the main source of this molecule in the tumor microenvironment (32), (33). From MMP biology, we understand that a high level of MMP is a risk factor for cancer-related events, such as recurrence and disease-related death. This explains why in our study the accuracy of MMP2 as prognostic biomarker was better for DSS than for OS, both in univariate and multivariate analysis. It is well known that HNSCC patients have a reduced cancer-independent life expectancy, which explains the differences observed between OS and DSS (34). In this line, in the TCGA data, MMP2 was co-expressed with MMP1, MMP9 and MMP14 in HNSCC, but the authors did not report the impact of any MMP on OS in HNSCC (35). The absence of DSS evaluation may explain this discrepancy. Beyond prognosis, MMP were also candidate therapeutic targets in cancer, but, so far, most molecules failed in their development because of their toxicities (36). Selective inhibitors are still in development (37), (NCT03486730), as well as other drugs that have an indirect effect on MMP (38).
Clinical and histopathological parameters fail to identify around 25% of high-risk patients. Here, we propose that combining MMP2 status to those parameters would improve patients' risk stratification.
MMP2-high tumor bearing patients could be proposed for an intensified therapeutic plan, as compared to standard of care. MMP2 status may be defined pre-operatively on the initial biopsy, or post-operatively if analyzed on the resection specimen ( Fig S6) . Pre-operative stratification would guide neoadjuvant treatment such as immunotherapy or chemotherapy, when post-operative stratification would guide adjuvant treatment. The latter setting is particularly important for ENE negative patients who may, in some cases, not be offered any adjuvant treatment. To address the question of the best (neo)adjuvant treatment option in high risk patients, we measured the expression of an 18-gene signature predictive of response to PD-1 blockade. This signature was established on a large cohort of patients treated by pembrolizumab for head and neck cancers (n=107), melanoma (n=89) and other cancers (n=119) (16) . The fact that this signature was established by merging the data from 22 different types of cancers and limited to advanced and recurrent cancers might not reflect the clinical setting of the present study. However, PDL1 and interferon gamma response genes (STAT1, CXCL9, IDO1, HLADR, HLADQ) were part of this 18-gene signature and were identified as predictive of response to neoadjuvant pembrolizumab in a window-of-opportunity trial including untreated head and neck cancer patients (13) . Therefore, this 18G signature may be used to estimate expected response rates to PD-1 blockade of untreated OCSCC. There was no difference in expression of the 18G score among the different prognostic groups defined by our multivariate analysis for DSS, DFS and OS. In this line, using soluble CXCL9 and CXCL10 as surrogates for tumor T cell infiltration, or direct measures of frequencies of tumor-infiltrating T cells by flow cytometry, we observed that soluble MMP2 levels were not associated to T cell infiltration. Similar results were previously described for MMP2 measured by IHC in endometrial cancer (39). From these results, we may estimate that the proportion of patients expected to respond to PD-1 blockade should be similar in the different prognostic groups, leaving immunotherapy as a valid treatment option. Patient stratification in future OCSCC trials and clinical practice would definitely benefit from robust biomarkers used in combination with clinical variables, such as our MMP2 / ENE scoring, and with predictive biomarkers for final treatment decision-making.
MATERIALS AND METHODS
Patients and cohorts
Tumor and juxtatumor samples were obtained from operative specimens from previously untreated head and neck cancer patients. Patients with previous head and neck radiotherapy or chemotherapy were excluded. Juxta-tumor samples were taken on the specimens' margins, at least 1cm away from the tumor.
Three cohorts of patients treated in our anti-cancer center were included in this study. All analysis on secretome presented in Fig.1 For outcomes analysis, we used 3 survivals: disease free survival, in which the censoring event was the first occurrence of recurrence, disease specific survival, in which the censoring event was the occurrence of death caused by the evolution of the cancer (to the exclusion of treatment related toxicities and postoperative complications), and overall survival. We also used a binary criteria of severity defined as present in cases of DSS < 36 months and /or a DFS < 12 months without subsequent remission (unsuccessful salvage procedures and/or permanent palliative treatment); we considered that these criteria define the population with the most urgent need for prognosis biomarkers (41). This study was done in compliance with the principles of Good Clinical Practice and the Declaration of Helsinki. All patients signed a consent form mentioning that their operative specimens might be used for scientific purposes, and 12 of the 18 patients cohort were also included in the clinical trial NCT03017573. 
Tumor and juxta-tumor secretome analysis
Analysis of CD3 and CD8 infiltration by Flow Cytometry
Details are available at (42). Briefly, single-cell suspensions were obtained from enzymatically digested tumor samples, then filtered, washed, counted and stained for 15 minutes with DAPI (Miltenyi Biotec) to exclude dead cells, CD3 (Alexa700, clone UCHT1, from BD, #557943) and CD8b (PC5, clone 2ST8.5H7, from Beckman Coulter, #6607109) antibodies, among other antibodies (data not used in the present paper), before phenotyping by flow cytometry (BD LSRFortessa Analyzer).
Gene expression analysis by Real-Time RT-PCR
Samples and RNA Extraction
Tumor and juxtatumor samples were snap-frozen in liquid nitrogen upon surgical removal after pathologist's review and were stored in the corresponding our biological resources center. Samples were sectioned using Tissue-Tek optimal cutting temperature (O.C.T) compound to estimate the percentage of tumor cells and to remove non-malignant tissue by macrodissection if necessary. Median percentage of tumor cells was 80% (range 40-95). RNA extraction was performed on the same sample, using the miRNeasy miniKit (Qiagen) according to the manufacturer's protocol. RNA was quantified using Nanodrop spectrophotometer ND-1000 and the integrity and purity were assessed by the Agilent 2100
Bioanalyzer and RNA 6000 Nano Labchip Kit (Agilent Biotechnologies, Palo Alto, CA, USA).
Total RNA was extracted from 145 OCSSC and 31 juxtatumor frozen samples from HNSCC bearing patients by using the acid-phenol guanidium method. RNA samples quality was assessed by electrophoresis through agarose gels and staining with ethidium bromide, and the 18S and 28S RNA bands were visualized under UV light. 
PCR Amplification and quantification
All of the PCR reactions were performed using an ABI Prism 7900HT Sequence Detection system (Thermo Fisher Scientific, Waltham, Massachusetts). PCR was performed using the Power SYBR™ Green PCR Master Mix (Life Technologies, Carlsbad, Californie). The thermal cycling conditions comprised an initial denaturation step of 10min at 95°C followed by 50 cycles at 95°C for 15 s and 65°C for 1 min. Cycle Threshold (Ct value) was defined by the cycle number at which the increase in the fluorescence signal associated with exponential growth of PCR products started to be detected, using Applied Biosystems analysis software according to the manufacturer's manuals. For quality controls, we quantified the housekeeping gene TBP (Genbank accession NM_003194). Primers for TBP and the 30 target genes were designed with the assistance of Oligo 6.0 computer program (National Biosciences, Plymouth, MN). dbEST and nr databases were used to confirm the total gene specificity of the nucleotide sequences chosen as primers and the absence of single nucleotide polymorphisms. The primer pairs selected were unique relative to the sequences of closely related family member genes and the corresponding retropseudogenes. One of the two primers was placed at the junction between two exons or on two different exons to avoid genomic DNA contaminating. Specificity of PCR amplicons was verified by agarose gel electrophoresis. The oligonucleotide primers sequences used are shown in Table S8 . The 30 genes of this study are listed in Table S5 . To obtain a score for the 18 genes signature, we 
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